| abstract |
The present invention comprises (i) a fusion protein comprising an ε s2 -CH4 domain portion and an antibody portion that specifically recognizes extra domain B of fibronectin (ED-B-fibronectin), and (ii) anti-EGFR- The antibody combination and its use for the treatment of cancer, in particular head and neck cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer, pancreatic cancer, gastric cancer and / or breast cancer. |